438 related articles for article (PubMed ID: 30068236)
1. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
Hu J; Zou P; Zhang S; Zhou M; Tan X
Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
[TBL] [Abstract][Full Text] [Related]
3. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
Gallwitz B
Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
Rizos CV; Filippatos TD; Elisaf MS
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
[TBL] [Abstract][Full Text] [Related]
5. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin: A Review in Type 2 Diabetes.
Frampton JE
Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
[TBL] [Abstract][Full Text] [Related]
7. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
Tahrani AA
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):678-9. PubMed ID: 24948512
[No Abstract] [Full Text] [Related]
8. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X; Hu J
Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
Levine MJ
Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Jain RK
Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects.
Rojas C; Link J; Meinicke T; Macha S
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):282-92. PubMed ID: 26932302
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
18. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin/metformin (Synjardy) for type 2 diabetes.
Med Lett Drugs Ther; 2015 Dec; 57(1484):172-4. PubMed ID: 26670554
[No Abstract] [Full Text] [Related]
20. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]